BRANFORD, Conn., Oct. 18 /PRNewswire/ -- HistoRx announced that Heiner Dreismann, Ph.D. has accepted its invitation to join the Board of Directors. As the former President and CEO of Roche Molecular Systems, Dr. Dreismann is an acknowledged diagnostic industry expert.
Dr. Dreismann was with Hoffmann La Roche for twenty years serving in several roles, including Head of Global Business Development Roche Diagnostics, Head of PCR Business Unit for Europe, President and CEO of Roche Molecular Systems and member of the global Executive Committee of Roche Diagnostics. HistoRx CEO Rana K. Gupta approached Dr. Dreismann with the opportunity, commenting, "As we reach the commercialization stage of our diagnostics portfolio it's important to add knowledgeable experts from the global distribution companies that have brought new technologies forward to labs around the world. Heiner's experience with the launch and market development of PCR, and his familiarity with key decision makers across the diagnostics industry make him a valuable addition to the HistoRx Board."
"I am pleased to join the board of directors of HistoRx, a company that has developed a unique and innovative technology to address the key unmet need of the pathology community," Dreismann stated. "HistoRx products have great potential in the United States and overseas markets."
About HistoRx (www.historx.com)
HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care. The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis. AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making. HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights. For more information please visit www.historx.com.
SOURCE HistoRx, Inc.